FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes
Anagrelide - Wikipedia
Teva Recalls One Lot of Anagrelide Capsules, USP 0.5 mg Due to Dissolution Test Failure | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
Teva Pharma Recalls One Lot Of Anagrelide Capsules
Anagrelide_ Teva Pharmaceuticals USA Inc_05.23.22.docx
FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes
These highlights do not include all the information needed to use ANAGRELIDE CAPSULES safely and effectively. See full prescribing information for ANAGRELIDE CAPSULES. ANAGRELIDE capsules, for oral useInitial U.S. Approval: 1997
Agrylin/anagrelide (@Anagrelide) / Twitter
Anagrelide Teva 0,5 mg, harde capsules
Anagrelide Capsules USP 0.5mg 100s - GDMedz
Logo 5241 0.5 mg Pill Gray White Capsule-shape - Pill Identifier
Anagrelide, imported, 100cap
Logo 5240 1 mg Pill White Capsule-shape - Pill Identifier
Teva Recalls One Lot of Anagrelide Capsules, USP 0.5 mg Because It Failed Dissolution Test | Legal Giant
Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Anagrelide Capsules, USP Due to Dissolution Test Failure - US Recall News
Torrent Pharmaceuticals Recall Anagrelide Capsules over drug's Dissolution test Failure • Drugwatcher.org
Tieva Anagrelide Capsules USP, For Hospital
Teva Issues Voluntary Nationwide Recall of One Lot of Anagrelide Capsules | DAIC
Torrent Pharmaceuticals Recall Anagrelide Capsules over drug's Dissolution test Failure • Drugwatcher.org
Teva recalls one lot of thrombocythemia med anagrelide in the U.S.